A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy Of Eculizumab In Patients With Relapsing Neuromyelitis Optica (NMO)
Latest Information Update: 04 Jun 2024
At a glance
- Drugs Eculizumab (Primary)
- Indications Neuromyelitis optica
- Focus Registrational; Therapeutic Use
- Acronyms PREVENT
- Sponsors Alexion AstraZeneca Rare Disease
- 18 Apr 2024 Results assessing efficacy and safety of eculizumab and ravulizumab from PREVENT and CHAMPION-NMOSD trils presented at the 76th Annual Meeting of the American Academy of Neurology 2024.
- 08 Apr 2024 According to an Alexion Pharmaceuticals media release, company will present oral presentation highlighting results from this trial at the American Academy of Neurology (AAN) Annual Meeting in Denver, CO, 13 to 18 April 2024
- 18 Oct 2023 According to an AstraZeneca media release, Soliris (eculizumab) has been approved by the National Medical Products Administration (NMPA) in China for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD).